IQVIA (NYSE:IQV – Get Rating) had its target price boosted by research analysts at Deutsche Bank Aktiengesellschaft from $250.00 to $290.00 in a report released on Tuesday, The Fly reports. The firm presently has a “buy” rating on the medical research company’s stock. Deutsche Bank Aktiengesellschaft’s price target points to a potential upside of 21.18% from the company’s current price.
Several other brokerages have also issued reports on IQV. Mizuho dropped their target price on shares of IQVIA from $300.00 to $270.00 and set a “buy” rating for the company in a research report on Monday, March 7th. UBS Group dropped their target price on shares of IQVIA from $310.00 to $290.00 in a research report on Wednesday, February 16th. StockNews.com started coverage on shares of IQVIA in a research report on Thursday, March 31st. They set a “buy” rating for the company. Morgan Stanley dropped their target price on shares of IQVIA from $290.00 to $280.00 and set an “overweight” rating for the company in a research report on Wednesday, February 16th. Finally, Piper Sandler lowered their price objective on shares of IQVIA from $261.00 to $231.00 and set a “neutral” rating for the company in a report on Thursday, February 17th. Two equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $278.61.
IQV stock opened at $239.31 on Tuesday. The firm has a 50 day moving average of $231.38 and a 200-day moving average of $247.84. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 1.99. IQVIA has a 12 month low of $207.86 and a 12 month high of $285.61. The firm has a market capitalization of $45.69 billion, a P/E ratio of 48.25, a price-to-earnings-growth ratio of 2.22 and a beta of 1.46.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its stake in shares of IQVIA by 1.7% in the first quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 356,730 shares of the medical research company’s stock worth $82,479,000 after buying an additional 5,807 shares during the period. Alliance Wealth Advisors LLC increased its stake in shares of IQVIA by 11.0% in the first quarter. Alliance Wealth Advisors LLC now owns 2,176 shares of the medical research company’s stock worth $503,000 after buying an additional 215 shares during the period. First American Trust FSB increased its stake in shares of IQVIA by 4.1% in the first quarter. First American Trust FSB now owns 20,833 shares of the medical research company’s stock worth $4,816,000 after buying an additional 817 shares during the period. NuWave Investment Management LLC purchased a new position in shares of IQVIA in the first quarter worth $74,000. Finally, Dividend Assets Capital LLC purchased a new position in IQVIA during the 1st quarter valued at $27,000. 86.66% of the stock is currently owned by institutional investors.
IQVIA Company Profile (Get Rating)
IQVIA Holdings Inc provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
- Get a free copy of the StockNews.com research report on IQVIA (IQV)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Ross Stores On The Verge Of Major Rally
- Insiders Are Selling Palo Alto Networks
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.